Current stock page

Financial Data

TNGX Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

TNGXTango Therapeutics, Inc.

Healthcare / Biotechnology

Relative Leader / Watch

Sector Leader

NeutralEdge 10/10
$25.50+$0.65 (+2.62%)

Latest quote

  • Momentum
    60
  • Value
    —
  • Quality
    73
  • Risk resilience
    38
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$0$0$0$0$53.81M$3.18M$5.39M$4.12M
Gross Profit$0$0-$463K-$479K$53.81M$2.56M$5.39M$4.12M
Operating Income-$78.12M-$59.79M-$48.77M-$41.86M$14.07M-$40.97M-$42.53M-$40.91M
Net Income-$68.39M-$55.34M-$45.51M-$38.75M$15.88M-$38.85M-$39.88M-$37.67M
EPS-$0.39-$0.37-$0.32-$0.3$0.14-$0.35-$0.36-$0.34
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow-$37.14M-$38.87M-$44.36M-$29.72M-$30.95M-$36.52M-$41.7M-$36.65M
Capital Expenditure-$77K$0$0-$222K-$151K-$624K-$51K-$124K
Free Cash Flow-$37.22M-$38.87M-$44.36M-$29.94M-$31.1M-$37.14M-$41.75M-$36.77M
Net Cash Provided By Operating Activities-$37.14M-$38.87M-$44.36M-$29.72M-$30.95M-$36.52M-$41.7M-$36.65M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$1.03B$1.07B$435.79M$398.69M$210.14M$237.89M$274.31M$316.49M
Total Debt$31.18M$31.99M$32.79M$33.57M$34.76M$35.01M$36.95M$36.49M
Cash And Cash Equivalents$86.84M$345.56M$157.83M$112.28M$58.34M$39.27M$58.43M$69.53M
Total Liabilities$53.29M$49.35M$44.29M$52.51M$50.11M$102.94M$107.55M$116.98M
Total Stockholders Equity$980.17M$1.02B$391.51M$346.18M$160.03M$134.95M$166.76M$199.52M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio4.043.859.365.655.555.660.871.19
P/S ratio————————
Debt To Equity0.030.030.080.10.220.260.220.18
Free Cash Flow Yield-3.80%-3.65%-3.89%-7.16%-16.51%-19.53%-94.09%-55.82%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio4.043.859.365.655.555.660.871.19
P/S ratio————————
Return On Equity-21.22%-12.08%-27.39%-29.35%-62.81%-107.86%-79.32%-65.31%
Debt To Equity0.030.030.080.10.220.260.220.18

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe-18.48x
Pb4.52x
Revenue Growth Yoy-100.00%
EPS Growth Yoy-378.57%
Gross Margin0.00%
Operating Margin0.00%
ROE-30.34%
ROIC-22.59%
Debt To Equity0.03
FCF Yield-3.48%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$25.50
Volume2.71M
RSI (14)57.02
MACD0.24
MACD signal-0.1
MACD histogram0.35
ADX (14)12.99
SMA (50)$23.53
SMA (200)$22.90
ATR (14)$1.97
Historical volatility (annualized)100.25%
Volume (20-day average)4.19M

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score38/100
Beta1.61
Annual volatility101.07%
Max Drawdown-36.57%
Sharpe Ratio1.61
VaR (95%, 1-day)-7.87%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

TNGX Financial Data FAQ

What is Tango Therapeutics, Inc.'s revenue?

Tango Therapeutics, Inc.'s revenue is one of the core financial data points for TNGX. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Tango Therapeutics, Inc.'s revenue growing?

Revenue growth shows whether Tango Therapeutics, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is TNGX's EPS?

TNGX's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Tango Therapeutics, Inc.'s net income?

Tango Therapeutics, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Tango Therapeutics, Inc. generate?

Free cash flow shows how much cash Tango Therapeutics, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Tango Therapeutics, Inc. have?

Cash and debt help frame TNGX's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.